Study wrapper · #1251
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
Editor's note
A striking effect size in a high-risk population, and it lands the same week as a 13,000-patient EHR cohort pointing the same direction on semaglutide and cognition — the convergence is the story. Caution is still warranted: 246 patients, no randomization, and matching on age, sex, and BMI leaves room for confounding, since patients prescribed semaglutide may differ systematically from those given DPP-4 inhibitors. The very high background rate of cognitive impairment also suggests a frail cohort where small biases can loom large. A signal worth tracking into randomized territory.
Plain-language abstract
Italian researchers followed 246 elderly patients who have heart failure with preserved ejection fraction, obesity, and type 2 diabetes for one year. Those taking oral semaglutide developed new cognitive impairment at less than half the rate of matched patients taking DPP-4 inhibitor pills — about 27 versus 59 new cases per 100 patients per year, a 77% lower risk after statistical adjustment. Because patients were not randomly assigned to the two drugs, the study shows a strong association rather than proof of cause and effect.